CN101270380B - Screening method for hybrid tumor cell monoclonal preparation - Google Patents
Screening method for hybrid tumor cell monoclonal preparation Download PDFInfo
- Publication number
- CN101270380B CN101270380B CN 200810047640 CN200810047640A CN101270380B CN 101270380 B CN101270380 B CN 101270380B CN 200810047640 CN200810047640 CN 200810047640 CN 200810047640 A CN200810047640 A CN 200810047640A CN 101270380 B CN101270380 B CN 101270380B
- Authority
- CN
- China
- Prior art keywords
- preparation
- culture
- milliliter
- cell
- clone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims abstract description 16
- 238000012216 screening Methods 0.000 title claims abstract description 7
- 210000004881 tumor cell Anatomy 0.000 title claims description 7
- 210000004027 cell Anatomy 0.000 claims abstract description 36
- 239000002609 medium Substances 0.000 claims abstract description 15
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 206010003445 Ascites Diseases 0.000 claims abstract description 6
- 239000012228 culture supernatant Substances 0.000 claims abstract description 6
- 238000001514 detection method Methods 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 230000004927 fusion Effects 0.000 claims abstract description 4
- 239000001963 growth medium Substances 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 32
- 239000012452 mother liquor Substances 0.000 claims description 30
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 22
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 18
- 235000010981 methylcellulose Nutrition 0.000 claims description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 238000004321 preservation Methods 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 12
- 238000004659 sterilization and disinfection Methods 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 229920000609 methyl cellulose Polymers 0.000 claims description 10
- 239000001923 methylcellulose Substances 0.000 claims description 10
- 229930182555 Penicillin Natural products 0.000 claims description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 5
- 230000003321 amplification Effects 0.000 claims description 5
- 244000309466 calf Species 0.000 claims description 5
- 235000020776 essential amino acid Nutrition 0.000 claims description 5
- 239000003797 essential amino acid Substances 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 238000011177 media preparation Methods 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 150000002960 penicillins Chemical class 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 5
- 238000011146 sterile filtration Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 3
- 229960003896 aminopterin Drugs 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 abstract description 9
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 abstract description 5
- 238000004113 cell culture Methods 0.000 abstract description 3
- 230000007910 cell fusion Effects 0.000 abstract description 2
- 238000013341 scale-up Methods 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 1
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 5
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 4
- 235000019534 high fructose corn syrup Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229930182816 L-glutamine Natural products 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000024835 cytogamy Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000003328 fibroblastic effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 210000000776 antibody secreting cell Anatomy 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention relates to a method of realizing the screening and the monoclone preparation of hybridoma cell in one step. The method comprises that the semisolid medium of the monoclone of hybridoma cell is firstly prepared, the basic fibroblast growth factor of human is added into the fusion cell, then hydridoma fusion factor and clone factor are added and well-mixed, then the mixed material and the semisolid medium are gently well-mixed and packaged into plates and cultivated in the condition of 35 DEG C and CO2 with concentration of 5 percent; when visible clone colony grows in the plates, the clone is aspirated from the culture medium by a micropipettor and moved onto a cell culture plate for liquid scale-up culture, and one clone is moved in one hole; till the cell grows to half to two-third of the hole bottom, the culture supernatant is aspirated to do positive detection, and the positive hole is chosen to directly scale-up frozen and stored for further carrying out the characteristic identification of antibody or ascites production. The method of realizing the screening and the monoclone preparation of hybridoma cell in one step has the advantages of the simple operation, the short culture period, not requiring feeder cells and easily achieving the screening and the monoclone preparation of hybridoma cell after cell fusion in one step.
Description
Technical field
The present invention relates to a kind of method that can realize the cultivation preparation of filtering hybridoma and mono-clonal a step, belong to biological technical field.
Background technology
Since scientist Kohler in 1975 and Milstein created monoclonal antibody (McAb) technology, this technology development was perfect, and its application is also increasingly extensive.The cloning of fused cell is the steps necessary that obtains secretion monospecific antibody cell strain.At present.The method of fused cell cloning mainly contains following several:
Limiting dilution assay this be the present method that usually adopts of each laboratory.Namely after cytogamy, with the fused cell direct inoculation in containing HAT and selecting 96 or 24 orifice plates of substratum, through the detected positive hole of ELISA, within time as early as possible with its cell dilution to 4-8 cell/ml (being equivalent to 0.4-0.8 cell/every hole).From angle of statistics, this extent of dilution can make approximately that every hole, hole of 36% contains 1 cell, in the time of at the bottom of cell count grows to 10~50% holes, detects with ELISA, with detected positive hole clone more as stated above, until 90% above individual cells hole is the antibody-secreting positive.Limiting dilution assay is based on the Poisson regularity of distribution, and therefore cell counting is to obtain suitable dilution assurance exactly, could improve like this ratio of slender hilum.Owing to incessantly there being one to melt the platform Growth of Cells in every hole, squeezed by the hypertrophy of antibody-secreting negative cells by preventing positive colony, clone as early as possible positive cell very important, but this can cause necrocytosis or chromosome elimination unavoidably.Desirable result is according to above-mentioned extent of dilution, has in 20~50% hole Growth of Cells to occur.In addition, in liquid nutrient medium, fibroblastic growth is vigorous, also can hinder the growth of hybrid cell strain.Generally need at least 2~3 subclones with this method, because needs are cloned clone more repeatedly, the workload of cell cultures is large, complex operation, and cloning efficiency is low.Complex operation step, workload is large, length consuming time.
2. utilize the cell sorter (FACS) of fluorescence-activation: this method can select the positive cell of bouncing to carry out the cloning cultivation.But because the source and the quality that detect the required antigen coated fluorescence latex beads of positive cell are limit, also because the equipment of costliness is limit, this method fails to popularize.
3. soft agar semisolid medium method: due to agar fusing point higher (45~50 ℃), under room temperature, processing ease solidifies, and makes itself and cell be difficult for mixing, and cell distribution is uneven, and Growth of Cells is limited, and the clone selects difficulty and is difficult for detecting etc.
Summary of the invention
Technical problem to be solved by this invention is the deficiency that exists for above-mentioned prior art and provide a kind of simple to operate, and culture cycle is short, need not feeder cell, is easy to a step to realize the method for filtering hybridoma and monoclonal antibody preparation after cytogamy.
The present invention is that the technical scheme that the problem of the above-mentioned proposition of solution adopts is:
(1) 2 times of DMEM basic culture solutions of preparation: get
DulbeccoThe modified form culture medium dry powder is DMEM dry powder 10~15 grams, add 300~500 milliliters of pure water, add 3~5 gram sodium bicarbonates and abundant stirring and dissolving, regulate pH to 7.0~7.4 with 0.5~1.5 mole of every liter of hydrochloric acid and 0.5~1.5 mole of every liter of sodium hydroxide, filtration sterilization makes 2 times of DMEM basic culture solutions;
(2) preparation L-glutaminate mother liquor: take L-glutaminate 1~10 gram, add pure water 50-300 milliliter and be heated to dissolve fully, Sterile Filtration is prepared to such an extent that concentration is every liter of L-glutaminate mother liquor of 200 mmole, by 4 milliliters of packing of every pipe, and freezing preservation;
(3) preparation beta-mercaptoethanol mother liquor: get 50~80 microlitre beta-mercaptoethanols, join in the 50-120 ml pure water, filtration sterilization is prepared to get every liter of mother liquor of 10 mmole, freezing preservation;
(4) preparation methylated cellulose aqueous solution: take 0.6~2.4 gram 4000cp methylcellulose gum or Vltra tears, measure pure water, respectively 121~126 ℃ of sterilizations 30 minutes, measure 17.5~70 milliliters of pure water of having sterilized under aseptic condition and join gently in methylcellulose gum, stirred 20~24 hours under 2~8 ℃ of cold condition;
(5) HAT semisolid medium preparation: 15~60 milliliters of 2 times of DMEM basic culture solutions that add step (1) preparation in the methylated cellulose aqueous solution of step (4) preparation, 0.25~1 milliliter, the L-glutaminate mother liquor that adds step (2) preparation, 0.5~2 milliliter, the beta-mercaptoethanol mother liquor that adds step (3) preparation, add again: 10~40 milliliters of foetal calf serums, 0.5~2 milliliter of 100 times of commercially available MEM non-essential amino acid, 0.5~2 milliliter of the 10000 every ml penicillins of unit and every milliliter of Streptomycin sulphate mixed aqueous solution of 10000 micrograms, add 1~4 milliliter of 50 times of commercially available xanthoglobulin-aminopterin-induced syndromes-thymus pyrimidine solution (being commercially available 50 times of HAT solution), 2~8 ℃ were stirred 3~6 hours, namely obtain the HAT semisolid medium, it is also the hybrid tumor cell monoclonal semisolid medium,
(6) cell after the fusion was placed 35~38 ℃ of precultures 16~24 hours, then with 5~20 milliliters of 2 times of DMEM basic culture solution mixings that are preheated to step (1) preparation of 35~38 ℃, add mankind's Prostatropin (bFGF) 200-800 nanogram, adding hybridoma to merge and clone the factor is 0.5~2 milliliter of HFCS again, mixing, again with the HAT semisolid medium of step (5) preparation mixing gently, 35~38 ℃ of standing 10~30 minutes bubble removings side by side minute install to plate and 5% CO under 37 ℃
2Cultivate under condition;
(7) cultivated 9~14 days, plate or culture plate must not be taken out the incubator observation therebetween, treat to have grown in ware macroscopic clone's colony, to clone from this substratum with micropipet and draw, and move to Tissue Culture Plate and adopt the liquid amplification culture, every hole moves into 1 clone, at the bottom of cell grows to full hole 1/2~2/3 o'clock, draw culture supernatant and carry out positive detection, select positive hole directly to amplify frozen, further carry out antibody CHARACTERISTICS IDENTIFICATION or ascites production.
Press such scheme, described semisolid medium uses in a short time after preparation is completed and can be placed in 2~8 ℃ of preservations, if in long-time need not, need freezing preservation.
Press such scheme, described plate is diameter 35mm plate or 6 porocyte culture plates.
Fused cell of the present invention also can adopt the positive cell that needs subclone, is used for the hybrid tumor cell monoclonal semisolid medium and need not preculture.
HAT of the present invention need adopt xanthoglobulin-thymus pyrimidine HT to replace when carrying out the cell subclone.
Advantage of the present invention is: 1. media flow is large but be unlikely and affect cell and form the clone, can not solidify during operation, and is complete with cytomixis, selects convenience.2. fused cell is the colony growth, and is separated from one another, do not produce each other interference phenomenon, do not mix.3. each clone is formed by individual cells, does not therefore need repeatedly to clone to obtain single antibody secreting cell strain.4. clone the number showed increased, pick-up rate is high.Use this method, Single cell fusion (10
8Individual mouse boosting cell and 10
7Individual mouse myeloma SP2/O cell) altogether can obtain 900~1500 clones; And use limiting dilution assay, and reach the clone of same quantity, approximately need inoculate 230 96 orifice plates and could realize.Thereby greatly having alleviated the cell cultures workload, also significantly shorten experimental period.5. the hybridoma cell strain stability that obtains is strong.6. save the troublesome operation of preparation feeder cell, greatly reduced risk of pollution.7. effectively avoided being suppressed because fibroblastic growth makes the growth of hybridoma.
Embodiment
Embodiment 1
(1) 2 times of DMEM basic culture solution preparation: get DMEM 13.4 grams, add 500 milliliters of pure water, add 3.8 gram sodium bicarbonates and abundant stirring and dissolving, transfer pH to 7.2 with 1 mole of every liter of hydrochloric acid and 1 mole of every liter of sodium hydroxide, filtration sterilization makes 2 times of DMEM basic culture solutions.
(2) L-glutaminate mother liquor preparation: take L-glutaminate (L-Glutamine, Invitrogen) 5.8 grams, add 200 milliliters of pure water, be heated to 50 ℃ and make dissolving fully, Sterile Filtration, obtain every liter of L-glutaminate mother liquor of 200 mmole, by 4 milliliters of packing of every pipe, put-20 ℃ of preservations.
(3) beta-mercaptoethanol mother liquor preparation: get 70 microlitre beta-mercaptoethanols, add in 100 ml pure waters, filtration sterilization obtains every liter of beta-mercaptoethanol mother liquor of 10 mmole ,-20 ℃ of preservations.
(4) methylated cellulose aqueous solution preparation: get 25 milliliters of 4000cp methylcellulose gum 0.6 gram and ultrapure waters and sterilized 30 minutes in 121~126 ℃, get 12.5 milliliters of pure water of having sterilized under aseptic condition and join gently in methylcellulose gum, 4 ℃ of cold condition lower magnetic forces stirred 24 hours.
(5) HAT semisolid medium preparation: 16 milliliters of 2 times of DMEM basic culture solutions that add step (1) preparation in the final solution of step (4), 0.27 milliliter, the L-glutaminate mother liquor of step (2) preparation, 0.5 milliliter, the beta-mercaptoethanol mother liquor of step (3) preparation, 12 milliliters of foetal calf serums, 0.5 milliliter of MEM non-essential amino acid, the 10000 every ml penicillins of unit add 0.5 milliliter of every milliliter of Streptomycin sulphate mixed aqueous solution of 10000 microgram, 1 milliliter of commercially available 50 times of HAT solution, 4 ℃ of magnetic agitation 4 hours.
(6) merge rear cell and placed 37 ℃ of precultures 18 hours, then with 5 milliliters of whole solution mixings that are preheated to step 1 preparation of 37 ℃, add mankind's Prostatropin (bFGF) 200 nanograms, 0.5 milliliter of HFCS, after mixing, mix 37 ℃ of standing 20 minutes bubble removings side by side with the HAT semisolid medium of step 5 preparation, be sub-packed in plate, be placed on 37 ℃, 5% CO
2Cultivate under condition.
(7) cultivated 9~14 days, plate or culture plate must not be taken out the incubator observation therebetween, treat to grow in ware macroscopic clone's colony, will clone from this substratum with micropipet and draw, move to 96 porocyte culture plate liquid amplification culture, every hole moves into 1 clone.At the bottom of growing to full hole 1/2~2/3 o'clock, draw culture supernatant and carry out positive detection, select positive hole directly to amplify frozen, further carry out antibody CHARACTERISTICS IDENTIFICATION or ascites production.
Embodiment 2
(1) 2 times of DMEM basic culture solution preparation: get DMEM 13.4 grams, add 500 milliliters of pure water, add 3.8 gram sodium bicarbonates and abundant stirring and dissolving, transfer pH to 7.4 with 1 mole of every liter of hydrochloric acid and 1 mole of every liter of sodium hydroxide, filtration sterilization makes 2 times of DMEM basic culture solutions.
(2) L-glutaminate mother liquor preparation: take L-glutaminate (L-Glutamine, Invitrogen) 2.9 grams, add 100 milliliters of pure water, be heated to 52 ℃ and make dissolving fully, Sterile Filtration, obtain every liter of L-glutaminate mother liquor of 200 mmole, by 4 milliliters of packing of every pipe, put-20 ℃ of preservations.
(3) beta-mercaptoethanol mother liquor preparation: get 63 microlitre beta-mercaptoethanols, add in 90 ml water solution, filtration sterilization obtains every liter of beta-mercaptoethanol mother liquor of 10 mmole ,-20 ℃ of preservations.
(4) methylated cellulose aqueous solution preparation: get 25 milliliters of 4000cp methylcellulose gum 0.6 gram and pure water and sterilized 30 minutes in 121~126 ℃, get 12.5 milliliters of pure water of having sterilized under aseptic condition and join gently in methylcellulose gum, 4 ℃ of cold condition lower magnetic forces stirred 24 hours.
(5) HAT semisolid medium preparation: 15 milliliters of 2 times of DMEM basic culture solutions that add step (1) preparation in the final solution of step (4), 0.25 milliliter, the L-glutaminate mother liquor of step (2) preparation, 0.5 milliliter, the beta-mercaptoethanol mother liquor of step (3) preparation, 10 milliliters of foetal calf serums, 1 milliliter of MEM non-essential amino acid, the 10000 every ml penicillins of unit add 0.5 milliliter of every milliliter of Streptomycin sulphate mixed aqueous solution of 10000 microgram, 2 milliliters of commercially available 50 times of HAT solution, 4 ℃ of magnetic agitation 4 hours.
(6) merge rear cell and placed 37 ℃ of precultures 21 hours, then be preheated to the whole solution mixing of step 1 preparation of 37 ℃ with 10mL, add mankind's Prostatropin (bFGF) 400 nanograms, 1 milliliter of HFCS, after mixing, mix 37 ℃ of standing 20 minutes bubble removings side by side with the HAT semisolid medium of step 5 preparation, be sub-packed in plate, be placed on 37 ℃, 5% CO
2Cultivate under condition.
(7) cultivated 9~14 days, plate or culture plate must not be taken out the incubator observation therebetween, treat to grow in ware macroscopic clone's colony, will clone from this substratum with micropipet and draw, move to 96 porocyte culture plate liquid amplification culture, every hole moves into 1 clone.At the bottom of growing to full hole 1/2~2/3 o'clock, draw culture supernatant and carry out positive detection, select positive hole directly to amplify frozen, further carry out antibody CHARACTERISTICS IDENTIFICATION or ascites production.
Embodiment 3
(1) 2 times of DMEM basic culture solution preparation: get DMEM 13.4 grams, add 500 milliliters of pure water, add 3.8 gram sodium bicarbonates and abundant stirring and dissolving, transfer pH to 7.2 with 1 mole of every liter of hydrochloric acid and 1 mole of every liter of sodium hydroxide, filtration sterilization makes 2 times of DMEM basic culture solutions.
(2) L-glutaminate mother liquor preparation: take L-glutaminate (L-Glutamine, Invitrogen) 8.7 grams, add 150 milliliters of pure water, be heated to 50 ℃ and make dissolving fully, Sterile Filtration, obtain every liter of L-glutaminate mother liquor of 200 mmole, by 4 milliliters of packing of every pipe, put-20 ℃ of preservations.
(3) beta-mercaptoethanol mother liquor preparation: get 77 microlitre beta-mercaptoethanols, add in 110 ml water solution, filtration sterilization obtains every liter of beta-mercaptoethanol mother liquor of 10 mmole ,-20 ℃ of preservations.
(4) methylated cellulose aqueous solution preparation: get 25 milliliters of 4000cp methylcellulose gum 0.9 gram and pure water and sterilized 30 minutes in 121~126 ℃, get 12.5 milliliters of pure water of having sterilized under aseptic condition and join gently in methylcellulose gum, 4 ℃ of cold condition lower magnetic forces stirred 24 hours.
(5) HAT semisolid medium preparation: 16 milliliters of 2 times of DMEM basic culture solutions that add step (1) preparation in the final solution of step (4), 0.3 milliliter, the L-glutaminate mother liquor of step (2) preparation, 0.6 milliliter, the beta-mercaptoethanol mother liquor of step (3) preparation, 18 milliliters of foetal calf serums, 0.8 milliliter of MEM non-essential amino acid, the 10000 every ml penicillins of unit add 0.5 milliliter of every milliliter of Streptomycin sulphate mixed aqueous solution of 10000 microgram, 1 milliliter of commercially available 50 times of HAT solution, 4 ℃ of magnetic agitation 4 hours.
(6) get the hybridoma that needs subclone and be preheated to 5 milliliters the whole solution mixings that the step 1 of 37 ℃ is prepared, add mankind's Prostatropin (bFGF) 200 nanograms, 0.5 milliliter of HFCS, after mixing, mix with the HAT semisolid medium of step 5 preparation, 37 ℃ of standing 20 minutes bubble removings side by side are sub-packed in plate, are placed on 37 ℃, 5% CO
2Cultivate under condition.
(7) cultivated 9~14 days, plate or culture plate must not be taken out the incubator observation therebetween, treat to grow in ware macroscopic clone's colony, to clone from this substratum with micropipet and draw, and move to 96 porocyte culture plate liquid amplification culture, every hole moves into 1 clone, at the bottom of growing to full hole 1/2~2/3 o'clock, draw culture supernatant and carry out positive detection, select positive hole directly to amplify frozen, further carry out antibody CHARACTERISTICS IDENTIFICATION or ascites production.
Claims (2)
1. the screening method of a hybrid tumor cell monoclonal preparation, is characterized in that
(1) 2 times of DMEM basic culture solutions of preparation: getting Dulbecco modified form culture medium dry powder is DMEM dry powder 10~15 grams, add 300~500 milliliters of pure water, add 3~5 gram sodium bicarbonates and abundant stirring and dissolving, regulate pH to 7.0~7.4 with 0.5~1.5 mole of every liter of hydrochloric acid and 0.5~1.5 mole of every liter of sodium hydroxide, filtration sterilization makes 2 times of DMEM basic culture solutions;
(2) preparation L-glutaminate mother liquor: take L-glutaminate 1~10 gram, add pure water 50-300 milliliter and be heated to dissolve fully, Sterile Filtration is prepared to such an extent that concentration is every liter of L-glutaminate mother liquor of 200 mmole, by 4 milliliters of packing of every pipe, and freezing preservation;
(3) preparation beta-mercaptoethanol mother liquor: get 50~80 microlitre beta-mercaptoethanols, join in the 50-120 ml pure water, filtration sterilization is prepared to get every liter of mother liquor of 10 mmole, freezing preservation;
(4) preparation methylated cellulose aqueous solution: take 0.6~2.4 gram 4000cp methylcellulose gum or Vltra tears, measure pure water, respectively 121~126 ℃ of sterilizations 30 minutes, measure 17.5~70 milliliters of pure water of having sterilized under aseptic condition and join in methylcellulose gum, stirred 20~24 hours under 2~8 ℃ of cold condition;
(5) HAT semisolid medium preparation: 15~60 milliliters of 2 times of DMEM basic culture solutions that add step (1) preparation in the methylated cellulose aqueous solution of step (4) preparation, 0.25~1 milliliter, the L-glutaminate mother liquor that adds step (2) preparation, 0.5~2 milliliter, the beta-mercaptoethanol mother liquor that adds step (3) preparation, add again: 10~40 milliliters of foetal calf serums, 0.5~2 milliliter of 100 times of commercially available MEM non-essential amino acid, 0.5~2 milliliter of the 10000 every ml penicillins of unit and every milliliter of Streptomycin sulphate mixed aqueous solution of 10000 micrograms, add 50 times of commercially available xanthoglobulin-aminopterin-induced syndromes-1~4 milliliter of thymus pyrimidine solution, 2~8 ℃ were stirred 3~6 hours, namely obtain the HAT semisolid medium, it is also the hybrid tumor cell monoclonal semisolid medium,
(6) cell after the fusion was placed 35~38 ℃ of precultures 16~24 hours, then with 5~20 milliliters of 2 times of DMEM basic culture solution mixings that are preheated to step (1) preparation of 35~38 ℃, add mankind's HBGH-2 00-800 nanogram, add again hybridoma to merge and clone's factor is HFCS0.5~2 milliliter, mixing, again with the HAT semisolid medium of step (5) preparation mixing gently, 35~38 ℃ of standing 10~30 minutes bubble removings side by side minute install to plate and 5% CO under 37 ℃
2Cultivate under condition;
(7) cultivated 9~14 days, plate or culture plate must not be taken out the incubator observation therebetween, treat to have grown in ware macroscopic clone's colony, to clone from this substratum with micropipet and draw, and move to Tissue Culture Plate and adopt the liquid amplification culture, every hole moves into 1 clone, at the bottom of cell grows to full hole 1/2~2/3 o'clock, draw culture supernatant and carry out positive detection, select positive hole directly to amplify frozen, further carry out antibody CHARACTERISTICS IDENTIFICATION or ascites production.
2. by the screening method of hybrid tumor cell monoclonal preparation claimed in claim 1, it is characterized in that described plate is diameter 35mm plate or 6 porocyte culture plates.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200810047640 CN101270380B (en) | 2008-05-08 | 2008-05-08 | Screening method for hybrid tumor cell monoclonal preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200810047640 CN101270380B (en) | 2008-05-08 | 2008-05-08 | Screening method for hybrid tumor cell monoclonal preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101270380A CN101270380A (en) | 2008-09-24 |
CN101270380B true CN101270380B (en) | 2013-06-19 |
Family
ID=40004607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200810047640 Expired - Fee Related CN101270380B (en) | 2008-05-08 | 2008-05-08 | Screening method for hybrid tumor cell monoclonal preparation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101270380B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102864125B (en) * | 2012-08-08 | 2014-11-26 | 南京巴傲得生物科技有限公司 | Method for preparing monoclonal hybrid tumors |
CN103898060B (en) * | 2012-12-25 | 2015-12-23 | 深圳先进技术研究院 | The screening method of HAT semisolid screening culture medium and hybridoma |
CN103898061B (en) * | 2012-12-26 | 2016-04-13 | 深圳先进技术研究院 | Semisolid medium and preparation method thereof and filtering hybridoma method |
CN103898063B (en) * | 2012-12-26 | 2016-01-27 | 深圳先进技术研究院 | The screening method of semisolid screening culture medium and hybridoma |
CN103898062B (en) * | 2012-12-26 | 2016-04-13 | 深圳先进技术研究院 | Latex semisolid medium and preparation method thereof and filtering hybridoma method |
CN103278631B (en) * | 2013-04-03 | 2014-04-09 | 中国农业科学院油料作物研究所 | Aflatoxin B1 flow lag immunization time distinguishing fluorescence rapid-detection kit and application thereof |
CN110205301A (en) * | 2019-06-14 | 2019-09-06 | 扬州大学 | A kind of method of hybridoma cell clone |
CN111926019B (en) * | 2020-10-16 | 2020-12-25 | 和元生物技术(上海)股份有限公司 | H1 promoter with enhanced affinity for Pol II and Pol III |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1425774A (en) * | 2002-12-31 | 2003-06-25 | 中国科学院水生生物研究所 | Specific anti-round myxobolus monoclonal anti-body and its preparing method |
-
2008
- 2008-05-08 CN CN 200810047640 patent/CN101270380B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1425774A (en) * | 2002-12-31 | 2003-06-25 | 中国科学院水生生物研究所 | Specific anti-round myxobolus monoclonal anti-body and its preparing method |
Non-Patent Citations (2)
Title |
---|
《抗肠出血性大肠杆菌O157∶H7 EspA单克隆抗体的制备及其特性鉴定》;余抒等;《细胞与分子免疫学杂志》;20071231;第23卷(第7期);657-659 * |
余抒等.《抗肠出血性大肠杆菌O157∶H7 EspA单克隆抗体的制备及其特性鉴定》.《细胞与分子免疫学杂志》.2007,第23卷(第7期),657-659. |
Also Published As
Publication number | Publication date |
---|---|
CN101270380A (en) | 2008-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101270380B (en) | Screening method for hybrid tumor cell monoclonal preparation | |
CN104630138B (en) | A kind of serum-free cultured chondrocytes liquid | |
CN103320390B (en) | Large-scale mammal engineering cell cultural method | |
CN103773732B (en) | The production technology of definite culture medium, its application and the large-scale culture mammalian cell of a kind of chemical composition | |
CN102858954A (en) | Improved cell cultivation process | |
CN102382794B (en) | Perfusion culture method of mammal cell | |
CN105132375A (en) | Serum-free medium for liver cancer stem cells and culture method for serum-free medium | |
CN103898041A (en) | Culture method of hybridomas | |
CN103898060B (en) | The screening method of HAT semisolid screening culture medium and hybridoma | |
CN101531996B (en) | Method for separating and purifying mesenchymal stem cells originated from formation tissue | |
CN101831403A (en) | Method for amplifying mesenchymal stem cells of human umbilical cord and placenta in vitro | |
JPH08508875A (en) | Fed-batch culture of protein-secreting cells | |
CN103103237B (en) | Method for cell perfusion culture to produce recombinant protein by microcarrier technology | |
CN103898063B (en) | The screening method of semisolid screening culture medium and hybridoma | |
CN112592948A (en) | Perfusion culture method of animal cells | |
CN107311756A (en) | The preparation method of new-type fertilizer containing polyglutamic acid | |
CN102002482B (en) | Method for producing PRRS (Porcine Reproductive and Respiratory Syndrome) viruses | |
CN101333513B (en) | Non-blood serum low density culture medium for animal cell and use thereof | |
CN101955983A (en) | Monoclonal antibody semisolid screening culture medium | |
CN101205530B (en) | Method for high-effectively expressing recombinant protein by employing animal cell fed-batch culture mode | |
CN104974933B (en) | A kind of extensive continuous several times, which suspend, turns the apparatus and method of expression recombinant protein wink | |
CN102864125B (en) | Method for preparing monoclonal hybrid tumors | |
CN101875926B (en) | Method for preparing liquid cellulase | |
CN103255238A (en) | Method for controlling generation of mammalian cell lactic acid | |
CN102604884B (en) | Fermentation culture method of cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130619 |
|
CF01 | Termination of patent right due to non-payment of annual fee |